Skip to main content

Table 2 Distribution of patients in the study groups and among randomized treatments

From: Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer

  A (pre-treatment) P (pre-treatment) T (pre-treatment) Total
  n ER-α-positive n ER-α-positive n ER-α-positive n ER-α-positive
ER- β-negative 11 9 12 9 5 3 28 21
ER- β-positive 13 9 16 14 18 13 47 36
ER-α/ER-β ratio < 1 5 2 5 2 8 4 18 8
ER-α/ER-β ratio between 1 and 1.5 9 7 7 6 6 5 22 18
ER-α/ER-β ratio > 1.5 10 9 16 15 9 7 35 31
  1. A: anastrozole group; P: placebo group; T: tamoxifen group.
  2. ER-α-positive: number of patients in each group considered positive to ER-α (final Allred score equal to or greater than 3).